| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006815 |
| Receipt No. | R000008048 |
| Scientific Title | Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study |
| Date of disclosure of the study information | 2011/12/01 |
| Last modified on | 2020/11/27 (Ver. 10) |
| Basic information | ||
| Public title | Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study | |
| Acronym | Outcome study of Lanthanum Carbonate compared with Calcium carbonate in hemodialysis patients: Landmark Study | |
| Scientific Title | Outcome study of Lanthanum Carbonate compared with Calcium carbonate on cardiovascular mortality and morbidity in patients with chronic kidney disease on hemodialysis: Landmark Study | |
| Scientific Title:Acronym | Outcome study of Lanthanum Carbonate compared with Calcium carbonate in hemodialysis patients: Landmark Study | |
| Region |
|
|
| Condition | ||
| Condition | Hemodialysis patients with hyperphosphatemia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To demonstrate decrease in cardiovascular mortality and morbidity in Japanese hemodialysis patients treated with Lanthanum Carbonate compared with those with Calcium Carbonate |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | Cardiovascular event free survival time
Following diseases were recognized; 1) death due to cardiovascular diseases including sudden cardiac death 2) nonfatal myocardial infarction 3) nonfatal cerebral stroke including transient ischemic attack, TIA 4) unstable angina 5) hospitalization for heart failure 6) hospitalization for ventricular arrhythmia |
| Key secondary outcomes | - overall survival
- secondary hyperparathyroidism free survival - hip fracture free survival - quality of life questionnaire (KDQOL-SF, v1.3) - bone mineral density (DEXA) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | |
| Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Lanthanum carbonate treatment (Patients will be followed for three years after the last patient is enrolled ) | |
| Interventions/Control_2 | Calcium carbonate treatment (Patients will be followed for three years after the last patient is enrolled ) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | - hemodialysis patients with hyperphosphatemia who require phosphate binders
- hemodialysis for more than 3 months - patients who have at lease one calcification risk factor (elderly > 65 years, postmenopausal woman, type 2 diabetes mellitus) - intact-PTH < or =240 pg/mL - life expectancy > 1 year - with written informed consent |
|||
| Key exclusion criteria | - contraindications to Ca carbonate and La carbonate
- swallowing disorders - severe GI disorders - history of obstructed bowels - history of IHD/stroke within 6 months - NYHA classification III-IV - severe liver dysfunction, AST or ALT greater than 3 times the upper limit of institution - require treatment of arrthythmia - severe malnutrition - malignancy of any type within the last 5 years - peritoneal dialysis patients - pregnant or possibly pregnant women or women on lactation and plan to get pregnant within study term - ineligible patients according to the investigator's judgment |
|||
| Target sample size | 3000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Showa University | ||||||
| Division name | Division of Nephrology, Department of Medicine | ||||||
| Zip code | 1428555 | ||||||
| Address | 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan | ||||||
| TEL | +81-3-3784-8000 | ||||||
| akizawa@med.showa-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Showa University Northern Yokohama Hospital | ||||||
| Division name | Department of Internal Medicine | ||||||
| Zip code | 2248503 | ||||||
| Address | 35-1 Chigasakichuo, Tsuzuki, Yokohama, Kanagawa, Japan | ||||||
| TEL | +81-45-949-7000 | ||||||
| Homepage URL | |||||||
| ogatah@med.showa-u.ac.jp | |||||||
| Sponsor | |
| Institute | Landmark Study Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Bayer Yakuhin, Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Foundation for Biomedical Research and Innovation at Kobe |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Showa University Clinical Trials Review Committee |
| Address | Hatanodai 1-5-8, Shinagawa, Tokyo, Japan |
| Tel | +81-3-3784-8000 |
| ctsc.admin@ofc.showa-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | NCT01578200 |
| Org. issuing International ID_1 | ClinicalTrials.gov |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 2347 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008048 |